Table 3:
Percentage of Total Adverse and Serious Adverse Events
| Author | Vaccine | Total Adverse events * %(N) |
Total Serious Adverse Events ** %(N) |
|---|---|---|---|
| Zhu, et al. [14] | adenovirus type-5 (Ad5)-vectored | 81 (87/108) | - |
| Zhu, et al. [15] | adenovirus type-5 (Ad5)-vectored | 60% (305/508) | 6.5 (25/382) |
| Jackson, et al. [16] | mRNA (mRNA-1273) | First dose: 53% (24/45) Second Dose: 80% (36/45) |
0 (0/45) |
| Folegatti, et al. [17] | ChAdOx1 nCoV-19 (SARS-CoV-2) vs. MenACWY (Control) | 53% (570/1077) | 0 (0/1077) |
| Xia, et al. [18] | Inactivated COVID-19 vaccine (Phase-I) | 15% (36/240) | 0 (0/240) |
| Xia, et al. [18] | Inactivated COVID-19 vaccine (Phase-II) | 13% (28/224) | - |
| Ramasamy, et al. [19] | ChAdOx1 nCoV-19 (SARS-CoV-2) vs. MenACWY (Control) | 17.3% (97/560) | - |
| Xia, et al. [20] | BBIBP-CorV | 29.2(42/144) | 0(0/144) |
| Xia, et al. [20] | BBIBP-CorV | - | - |
| Anderson, et al. [21] | mRNA (mRNA-1273) | First Dose: 40% (16/40) Second dose: 63% (25/40) Unsolicited Events irrespective of Dosing: 43%(17/40) |
- |
| Keech, et al. [22] | full-length wild-type SARS-CoV-2 spike glycoprotein | 32% (42/131) | - |
| Mulligan, et al. [23] | BNT162 mRNA vaccine candidates |
63% (15/24) | - |
| Walsh, et al. [24] | BNT162b1 and BNT162b2 | 26% (41/156) | - |
| Zhang, et al. [25] | CoronaVac (an inactivated vaccine candidate) | Phase 1: Dose 1:31% (15/48) Dose 2: 13% (6/48) Phase 2: Dose 1: 18% (43/240) Dose 2: 7% (17/235) |
- |
| Polack, et al. [26] | mRNA | 27% (11678/43252) | 0.01(4/43252) |
| Che, et al. [27] | Inactivated Vaccine | 24.5(146/595) | 0(0/595) |
*Total Adverse Events = the total number of solicited and unsolicited adverse events from first dose till follow-up
**Total Serious Adverse Events = the total number of solicited and unsolicited serious adverse events from first dose till follow-up